0001127602-22-008498.txt : 20220307
0001127602-22-008498.hdr.sgml : 20220307
20220307174927
ACCESSION NUMBER: 0001127602-22-008498
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20220303
FILED AS OF DATE: 20220307
DATE AS OF CHANGE: 20220307
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Spurr Robert
CENTRAL INDEX KEY: 0001543795
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-14956
FILM NUMBER: 22719552
MAIL ADDRESS:
STREET 1: C/O BAUSCH HEALTH COMPANIES INC.
STREET 2: 400 SOMERSET CORPORATE BLVD.
CITY: BRIDGEWATER
STATE: NJ
ZIP: 08807
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Bausch Health Companies Inc.
CENTRAL INDEX KEY: 0000885590
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: NJ
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 2150 ST. ELZEAR BLVD. WEST
STREET 2: LAVAL
CITY: QUEBEC
STATE: A8
ZIP: H7L 4A8
BUSINESS PHONE: 514-744-6792
MAIL ADDRESS:
STREET 1: 2150 ST. ELZEAR BLVD. WEST
STREET 2: LAVAL
CITY: QUEBEC
STATE: A8
ZIP: H7L 4A8
FORMER COMPANY:
FORMER CONFORMED NAME: Valeant Pharmaceuticals International, Inc.
DATE OF NAME CHANGE: 20100928
FORMER COMPANY:
FORMER CONFORMED NAME: BIOVAIL Corp
DATE OF NAME CHANGE: 20100416
FORMER COMPANY:
FORMER CONFORMED NAME: BIOVAIL CORP INTERNATIONAL
DATE OF NAME CHANGE: 19960522
4
1
form4.xml
PRIMARY DOCUMENT
X0306
4
2022-03-03
0000885590
Bausch Health Companies Inc.
BHC
0001543795
Spurr Robert
C/O BAUSCH HEALTH COMPANIES, INC.
400 SOMERSET CORPORATE BLVD.
BRIDGEWATER
NJ
08807
1
U.S. President-Pharma Business
Common Shares, No Par Value
2022-03-03
4
F
0
4074
23.61
D
96947
D
This number represents common shares, no par value, of the Issuer withheld to satisfy the tax withholding obligations due upon vesting of Restricted Share Units.
Due to an inadvertent administrative error, the reporting person previously filed a Form 4 on March 2, 2022 reporting the vesting of performance-based Restricted Share Units ("PSUs") on February 27, 2022. The Issuer's Talent and Compensation Committee of the Board certified the performance goals applicable to these PSUs on February 14, 2022, which was the correct date on which these PSUs performance-vested.
/s/ Debra E. Levin, attorney-in-fact for Robert A. Spurr
2022-03-07